Model designation 1R-3C-1PP-PG identifies (1R)-3-chloro-1-phenylpropan-1-ol as a pharmaceutical-grade chiral alcohol supplied for the downstream manufacture of oral and injectable dosage forms. The free base has molecular formula C₉H₁₁ClO and a molecular weight of 170.64 g/mol. The product is not formulated directly as a tablet or capsule drug substance; it functions as an API-grade chiral intermediate that is converted to the final active moiety before tableting, capsule filling, granulation, or injection. The (1R) configuration is retained during the synthesis of atomoxetine hydrochloride and related aryloxypropylamine pharmacophores, and the material is therefore used where stereochemical integrity at the benzylic carbon is critical. It is released as a white to off-white crystalline powder under ICH Q7 GMP controls. For oral solid dosage processing, the material is typically recrystallised, dried, and milled before final API formation; for injectable applications, the user must complete terminal sterilisation or aseptic processing, because the product is not supplied as a sterile ingredient. Published data for this specific non-compendial chiral intermediate are limited; therefore, the specification is controlled through a validated in-house analytical profile and batch data rather than a pharmacopoeial monograph. Batch-to-batch variability in crystal habit, residual solvent, and enantiomeric purity is monitored through statistical process control, and out-of-trend material is quarantined before release.

Differentiation from generic 3-chloro-1-phenylpropan-1-ol products is based on three controlled attributes: enantiomeric excess, residual solvent and elemental impurity profile, and batch-to-batch process documentation. The (1S)-enantiomer and racemic grades may be suitable for non-pharmaceutical syntheses but lack the validated analytical and regulatory package required for oral and injectable API manufacturing. The product code 1R-3C-1PP-PG serves as the commercial model identifier for the pharma-grade material described in this document.

What Controls Suitability for Oral Solid Dosage and Injectable Processing?

Fitness for oral solid and injectable manufacturing is established by control of residual solvents, elemental impurities, water content, microbiological burden, and particle-size distribution. The material is dried under vacuum at a product temperature not exceeding 50 °C to preserve chiral purity and remove process solvents. Residual solvent levels are measured by headspace gas chromatography using USP <467> Methodology A; the release specification holds dichloromethane at ≤600 ppm and methanol at ≤3000 ppm, consistent with ICH Q3C(R8) Class 2 limits for starting materials used in active ingredient synthesis. Elemental impurities are determined by inductively coupled plasma mass spectrometry according to USP <232> and USP <233>, with permissible daily exposure limits derived from ICH Q3D(R2) for oral and parenteral routes of administration. Water content is determined by Karl Fischer titration per USP <921>; the release criterion is ≤0.5 %. Microbiological quality is controlled because injectable processing requires a low bioburden before terminal sterilisation or aseptic filtration. The incoming non-sterile material is tested by membrane filtration according to USP <61> and USP <62> and released with total aerobic microbial count ≤100 CFU/g, total combined yeast and mould count ≤10 CFU/g, and absence of Escherichia coli, Salmonella species, Staphylococcus aureus, and Pseudomonas aeruginosa. Particle-size distribution is measured by laser diffraction according to ISO 13320:2020; D10, D50, and D90 are reported on the certificate of analysis. Tightened D90 specifications are available for direct-compression tablet formulations, while granule and capsule operations often use milled batches with controlled flow properties.

Table 1. Release specification and reference methods.

Enantiopurity Control During Asymmetric Reduction Work-Up

The stereochemical integrity of the molecule is governed by processing pH, temperature, and residence time. The benzylic alcohol centre can racemise through carbocation formation under strongly acidic conditions; elimination of HCl from the terminal chloropropyl group can also occur under strongly basic conditions. Published kinetic parameters for this exact substrate are limited. Process development therefore relies on forced-degradation studies in jacketed glass-lined reactors and on chiral HPLC tracking of the (1S)-alcohol. In production, the reaction mass is maintained at pH 6–8 and the jacket temperature is held below 60 °C during work-up and distillation. The crude alcohol is isolated by crystallisation rather than prolonged hot distillation; this limits thermal exposure at the chiral centre. The isolated product is dried at ≤50 °C and sampled at defined intervals for chiral purity. Scale-up records from agitated reactors show that the product remains within the ≤0.5 % (1S)-alcohol specification when the post-reaction hold time does not exceed 12 h; longer hold times require re-qualification. The chiral HPLC method uses an immobilised amylose-based chiral stationary phase with a methanol–carbon dioxide mobile phase or an n-hexane–ethanol mobile phase; the (1S)-enantiomer is resolved at baseline with a run time below 30 min. The method is qualified for specificity, linearity, accuracy, and repeatability following ICH Q2(R2) guidelines.

The production route involves asymmetric reduction of 3-chloro-1-phenylpropan-1-one. The catalyst and reducing agent are selected to suppress over-reduction of the phenyl ring and dehalogenation at the C3 chlorine. The exact catalyst system is defined in the batch master formula, but it must not generate metallic impurities above ICH Q3D(R2) limits. The work-up sequence includes aqueous extraction, pH adjustment, and crystallisation; each unit operation is performed in closed stainless-steel or glass-lined equipment to prevent moisture ingress and cross-batch contamination. The product is discharged through a nitrogen-purged glovebox and packed in sealed HDPE drums. This controlled isolation chain is a further point of difference from non-pharma-grade material, which is often drummed without controlled atmosphere or traceable cleaning validation data.

When the (1S)-Enantiomer or Racemic Grade Is Substituted

Substitution of this product with the (1S)-enantiomer changes the stereochemical course of downstream aryloxy displacement and yields the undesired enantiomer of the final aryloxypropylamine API. For atomoxetine hydrochloride, the (R)-configuration is required for pharmacological activity; the (S)-form is controlled as a chiral impurity. The use of racemic 3-chloro-1-phenylpropan-1-ol is not equivalent because the downstream product becomes a racemic mixture unless an additional chiral resolution step is introduced. That step increases processing burden by requiring chiral preparative chromatography or diastereomeric salt crystallisation and can reduce overall yield. The pharma-grade material is differentiated by the absence of routine chiral purification at the final API stage; the (1S)-alcohol is controlled at the intermediate stage, so final API enantiomeric purity is achieved without additional chiral separation.

Other generic chemical grades may have acceptable assay but do not consistently provide residual solvent and elemental impurity data in a format suitable for regulatory submission. Absence of ICH Q3C(R8) and ICH Q3D(R2) assessments shifts the compliance burden to the final API manufacturer; failure to control dichloromethane, methanol, and palladium or other catalyst residues can lead to out-of-specification results in finished dosage forms. The pharma-grade material is supplied with a certificate of analysis, batch traceability, and change-control documentation under ICH Q7. Finished dosage-form manufacturing for oral and injectable products must comply with 21 CFR 210/211 and the relevant pharmacopoeial monographs.

Table 2. Comparative profile against alternative chiral and non-chiral grades.

Direct tablet integration requires attention to particle-size distribution and moisture content. For tableting, the final API derived from this intermediate is blended with microcrystalline cellulose, crospovidone, magnesium stearate, and colloidal silicon dioxide; the particle-size distribution of the intermediate does not directly control final blend uniformity but influences downstream crystallisation and milling of the final API. For wet granulation, the API derived from this compound is granulated in a high-shear granulator with impeller tip speed controlled between 5 m/s and 15 m/s and binder addition based on wet mass torque. For capsule filling, the potency and flow characteristics of the final API are affected by the crystal habit generated during the downstream crystallisation, not by the intermediate itself. For injectable manufacture, the final API solution is filtered through a 0.22 µm sterilising-grade filter under nitrogen pressure; hold times before filtration are limited by bioburden and pH stability.

Storage in sealed HDPE drums under nitrogen at 2–8 °C is required. Exposure to relative humidity above 60 % RH should be avoided because the compound can agglomerate. The material should not be exposed to strong acids at elevated temperature, which may generate a benzyl carbocation and erode enantiopurity, or to strong bases, which may promote dehydrochlorination. Avoid contact with oxidising agents and avoid aqueous protic conditions above pH 8, because the terminal chloride can hydrolyse. For injectable processing, pre-filtration bioburden limits, filter compatibility, and final sterilisation parameters must be established by the finished-product manufacturer; the intermediate itself is not terminally sterilised.